The week ending 31-July-23 proves to be an interesting week for the pharmaceutical industry with multiple news of acquisition along with clinical and regulatory updates from many ongoing clinical trials across indications such as multiple sclerosis, chronic kidney disease, myasthenia gravis and metastatic breast cancer.
List of news are as follows:
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for marketing authorization for the first-of-its-kind biosimilar natalizumab developed by Polpharma Biologics, according to Sandoz, a global leader in off-patent (generic and biosimilar) medications.
Alnylam Pharmaceuticals Partners with Roche to Develop and Commercialize RNAi Therapeutic Zilebesiran
Roche announced on 24-July-2023, a fresh collaboration with Alnylam Pharmaceuticals to develop and market zilebesiran, a RNAi therapy now in Phase II for the management of hypertension.
Teva & Alvotech Provide Update on Strategic Biosimilars Partnership
Teva & Alvotech today disclosed their commitment to broaden their current strategic cooperation relationship. Additionally, Teva will purchase subordinated convertible bonds that Alvotech will be issuing.
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
Soliris approved in the EU for children and adolescents with refractory generalised myasthenia gravis (gMG)
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Biogen to Acquire Reata Pharmaceuticals
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) and Biogen Inc. (Nasdaq: BIIB) announced today that they have signed a formal agreement under which Biogen will buy Reata for $172.50 per share in cash, representing an enterprise value of around $7.3 billion.
